Market Research Reports and Industry Reports

Thromboembolism - Pipeline Review, H2 2015

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION

Summary
 
 Global Markets Direct’s, ‘Thromboembolism - Pipeline Review, H2 2015’, provides an overview of the Thromboembolism’s therapeutic pipeline.
 
 This report provides comprehensive information on the therapeutic development for Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thromboembolism and special features on late-stage and discontinued projects.
 
 Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
 
 The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
 
 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 
 Scope
 
 - The report provides a snapshot of the global therapeutic landscape of Thromboembolism
 - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
 - The report reviews key players involved in the therapeutics development for Thromboembolism and enlists all their major and minor projects
 - The report summarizes all the dormant and discontinued pipeline projects
 - A review of the Thromboembolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
 - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
 - A detailed assessment of monotherapy and combination therapy pipeline projects
 - Coverage of the Thromboembolism pipeline on the basis of target, MoA, route of administration and molecule type
 - Latest news and deals relating related to pipeline products
 
 Reasons to buy
 
 - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
 - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
 - Develop strategic initiatives by understanding the focus areas of leading companies
 - Identify and understand important and diverse types of therapeutics under development for Thromboembolism
 - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
 - Devise corrective measures for pipeline projects by understanding Thromboembolism pipeline depth and focus of Indication therapeutics
 - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
 - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents 2
 List of Tables 6
 List of Figures 7
 Introduction 8
 Global Markets Direct Report Coverage 8
 Thromboembolism Overview 9
 Therapeutics Development 10
 Pipeline Products for Thromboembolism - Overview 10
 Pipeline Products for Thromboembolism - Comparative Analysis 11
 Thromboembolism - Therapeutics under Development by Companies 12
 Thromboembolism - Therapeutics under Investigation by Universities/Institutes 14
 Thromboembolism - Pipeline Products Glance 15
 Late Stage Products 15
 Clinical Stage Products 16
 Early Stage Products 17
 Thromboembolism - Products under Development by Companies 18
 Thromboembolism - Products under Investigation by Universities/Institutes 19
 Thromboembolism - Companies Involved in Therapeutics Development 20
 Bayer AG 20
 Cereno Scientific AB 21
 China Biologic Products, Inc. 22
 Daiichi Sankyo Company, Limited 23
 Gamma Therapeutics, Inc. 24
 GlycoMimetics, Inc. 25
 Green Cross Corporation 26
 Isis Pharmaceuticals, Inc. 27
 Portola Pharmaceuticals, Inc. 28
 Sanofi 29
 The International Biotechnology Center (IBC) “Generium” 30
 Tobira Therapeutics, Inc. 31
 Thromboembolism - Therapeutics Assessment 32
 Assessment by Monotherapy Products 32
 Assessment by Target 33
 Assessment by Mechanism of Action 35
 Assessment by Route of Administration 37
 Assessment by Molecule Type 39
 Drug Profiles 41
 alteplase biosimilar - Drug Profile 41
 Product Description 41
 Mechanism of Action 41
 R&D Progress 41
 antithrombin III (human) - Drug Profile 42
 Product Description 42
 Mechanism of Action 42
 R&D Progress 42
 betrixaban - Drug Profile 43
 Product Description 43
 Mechanism of Action 43
 R&D Progress 43
 C-3 - Drug Profile 45
 Product Description 45
 Mechanism of Action 45
 R&D Progress 45
 edoxaban tosylate - Drug Profile 46
 Product Description 46
 Mechanism of Action 46
 R&D Progress 46
 Gammarin - Drug Profile 48
 Product Description 48
 Mechanism of Action 48
 R&D Progress 48
 GCC-2107 - Drug Profile 49
 Product Description 49
 Mechanism of Action 49
 R&D Progress 49
 GMI-1271 - Drug Profile 50
 Product Description 50
 Mechanism of Action 50
 R&D Progress 50
 ISIS-FXIRx - Drug Profile 51
 Product Description 51
 Mechanism of Action 51
 R&D Progress 51
 Lysimab - Drug Profile 52
 Product Description 52
 Mechanism of Action 52
 R&D Progress 52
 Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile 53
 Product Description 53
 Mechanism of Action 53
 R&D Progress 53
 Protein for Thromboembolism - Drug Profile 54
 Product Description 54
 Mechanism of Action 54
 R&D Progress 54
 REG-2 - Drug Profile 56
 Product Description 56
 Mechanism of Action 56
 R&D Progress 56
 rivaroxaban - Drug Profile 58
 Product Description 58
 Mechanism of Action 58
 R&D Progress 58
 semuloparin - Drug Profile 63
 Product Description 63
 Mechanism of Action 63
 R&D Progress 63
 Small Molecules to Inhibit HDAC for Thromboembolism - Drug Profile 64
 Product Description 64
 Mechanism of Action 64
 R&D Progress 64
 TAP-ANV - Drug Profile 65
 Product Description 65
 Mechanism of Action 65
 R&D Progress 65
 YG-001 - Drug Profile 66
 Product Description 66
 Mechanism of Action 66
 R&D Progress 66
 Thromboembolism - Recent Pipeline Updates 67
 Thromboembolism - Dormant Projects 88
 Thromboembolism - Discontinued Products 89
 Thromboembolism - Product Development Milestones 90
 Featured News & Press Releases 90
 Jul 12, 2015: NICE recommends edoxaban tosylate (Lixiana) for treating and preventing potentially fatal blood clots 90
 Jun 18, 2015: Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer 91
 Jun 03, 2015: NICE guidance recommends apixaban (Eliquis) for treating and preventing potentially fatal blood clots 91
 Apr 27, 2015: Daiichi Sankyo’s Once-Daily Lixiana (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Europe 92
 Apr 15, 2015: Daiichi Sankyo’s Once-Daily Lixiana (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Switzerland 93
 Mar 06, 2015: NICE draft guidance recommends apixaban (Eliquis) for treating and preventing potentially fatal blood clots 95
 Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO 96
 Dec 08, 2014: Daiichi Sankyo Launches New Formulation of LIXIANA 60 mg Tablets (edoxaban) in Japan 97
 Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery 97
 Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting 98
 Appendix 99
 Methodology 99
 Coverage 99
 Secondary Research 99
 Primary Research 99
 Expert Panel Validation 99
 Contact Us 99
 Disclaimer 100


List Of Tables

 Number of Products under Development for Thromboembolism, H2 2015 10
 Number of Products under Development for Thromboembolism - Comparative Analysis, H2 2015 11
 Number of Products under Development by Companies, H2 2015 13
 Number of Products under Investigation by Universities/Institutes, H2 2015 14
 Comparative Analysis by Late Stage Development, H2 2015 15
 Comparative Analysis by Clinical Stage Development, H2 2015 16
 Comparative Analysis by Early Stage Development, H2 2015 17
 Products under Development by Companies, H2 2015 18
 Products under Investigation by Universities/Institutes, H2 2015 19
 Thromboembolism - Pipeline by Bayer AG, H2 2015 20
 Thromboembolism - Pipeline by Cereno Scientific AB, H2 2015 21
 Thromboembolism - Pipeline by China Biologic Products, Inc., H2 2015 22
 Thromboembolism - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 23
 Thromboembolism - Pipeline by Gamma Therapeutics, Inc., H2 2015 24
 Thromboembolism - Pipeline by GlycoMimetics, Inc., H2 2015 25
 Thromboembolism - Pipeline by Green Cross Corporation, H2 2015 26
 Thromboembolism - Pipeline by Isis Pharmaceuticals, Inc., H2 2015 27
 Thromboembolism - Pipeline by Portola Pharmaceuticals, Inc., H2 2015 28
 Thromboembolism - Pipeline by Sanofi, H2 2015 29
 Thromboembolism - Pipeline by The International Biotechnology Center (IBC) “Generium”, H2 2015 30
 Thromboembolism - Pipeline by Tobira Therapeutics, Inc., H2 2015 31
 Assessment by Monotherapy Products, H2 2015 32
 Number of Products by Stage and Target, H2 2015 34
 Number of Products by Stage and Mechanism of Action, H2 2015 36
 Number of Products by Stage and Route of Administration, H2 2015 38
 Number of Products by Stage and Molecule Type, H2 2015 40
 Thromboembolism Therapeutics - Recent Pipeline Updates, H2 2015 67
 Thromboembolism - Dormant Projects, H2 2015 88
 Thromboembolism - Discontinued Products, H2 2015 89


List Of Figures

Number of Products under Development for Thromboembolism, H2 2015 10
 Number of Products under Development for Thromboembolism - Comparative Analysis, H2 2015 11
 Number of Products under Development by Companies, H2 2015 12
 Comparative Analysis by Late Stage Development, H2 2015 15
 Comparative Analysis by Clinical Stage Development, H2 2015 16
 Comparative Analysis by Early Stage Products, H2 2015 17
 Assessment by Monotherapy Products, H2 2015 32
 Number of Products by Top 10 Targets, H2 2015 33
 Number of Products by Stage and Top 10 Targets, H2 2015 33
 Number of Products by Top 10 Mechanism of Actions, H2 2015 35
 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 35
 Number of Products by Top 10 Routes of Administration, H2 2015 37
 Number of Products by Stage and Top 10 Routes of Administration, H2 2015 37
 Number of Products by Top 10 Molecule Types, H2 2015 39
 Number of Products by Stage and Top 10 Molecule Types, H2 2015 39


Venous thromboembolism (VTE) - Epidemiology Forecast To 2023

DelveInsight Venous thromboembolism (VTE) - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Venous thromboembolism (VTE) in seven major markets (US, France, Germany, Italy, Spain, UK

USD 2750View Report

United States Venous Thromboembolism Market Report 2016

Notes:Sales, means the sales volume of Venous ThromboembolismRevenue, means the sales value of Venous ThromboembolismThis report studies sales (consumption) of Venous Thromboembolism in United States market, focuses on the top

USD 3800View Report

Thromboembolism - Pipeline Review, H2 2016

Thromboembolism - Pipeline Review, H2 2016Global Markets Directs, Thromboembolism - Pipeline Review, H2 2016, provides an overview of the Thromboembolism pipeline landscape. The report provides comprehensive information on the therapeutics

USD 2000View Report

Global Blepharitis - Pipeline Market Research Report 2016

Notes:Production, means the output of Blepharitis - PipelineRevenue, means the sales value of Blepharitis - PipelineThis report studies Blepharitis - Pipeline in Global market, especially in North America, Europe, China,

USD 2900View Report

Japan Pancreatic Cancer - Pipeline Market Report 2016

Notes:Sales, means the sales volume of Pancreatic Cancer - PipelineRevenue, means the sales value of Pancreatic Cancer - PipelineThis report studies sales (consumption) of Pancreatic Cancer - Pipeline in Japan

USD 3400View Report

Japan Open-Angle Glaucoma - Pipeline Market Report 2016

Notes:Sales, means the sales volume of Open-Angle Glaucoma - PipelineRevenue, means the sales value of Open-Angle Glaucoma - PipelineThis report studies sales (consumption) of Open-Angle Glaucoma - Pipeline in Japan

USD 3400View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

Discount on PDF and Enterprise Wide Licence reports
  • PDF    $ 2000
  • Site Licence    $ 4000
  • Enterprise Wide Licence    $ 6000
$ 2000

Reports Details

Published Date : Jul 2015
No. of Pages :100
Country :Global
Category :Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment